Original articleFormulation and stability of an extemporaneous 0.02% Chlorhexidine digluconate (cas 18472-51-0) ophthalmic solution

Add time:09/08/2019    Source:sciencedirect.com

Background/PurposeAcanthamoeba keratitis is difficult to treat because Acanthamoeba cysts are resistant to the majority of antimicrobial agents. Despite the efficacy of 0.02% chlorhexidine in treating Acanthamoeba keratitis, a lack of data in the literature regarding the formulation's stability limits its clinical use. The objective of this study was to develop an optimal extemporaneous 0.02% Chlorhexidine digluconate (cas 18472-51-0) ophthalmic formulation for patients in need.

We also recommend Trading Suppliers and Manufacturers of Chlorhexidine digluconate (cas 18472-51-0). Pls Click Website Link as below: cas 18472-51-0 suppliers

Prev:Local facial atrophy and permanent anesthesia of right upper lip following subcutaneous extrusion of Chlorhexidine digluconate (cas 18472-51-0)
Next:Dual 0.02% Chlorhexidine digluconate (cas 18472-51-0) – 0.1% disodium EDTA loaded thermosensitive ocular gel for Acanthamoeba keratitis treatment)